Your session is about to expire
← Back to Search
Other
OKN-007 for Brain Tumor (OKN-007 Trial)
Phase 1
Waitlist Available
Led By James Battiste, MD, PhD
Research Sponsored by Oblato, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights
OKN-007 Trial Summary
This trial is testing a new cancer treatment in humans with recurrent malignant glioma. The treatment will be given intravenously and will be given to patients who have already tried the standard-of-care treatment, which includes surgery, radiation, and chemotherapy.
Eligible Conditions
- Brain Tumor
OKN-007 Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 24 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Number of Adverse events per patient
Secondary outcome measures
6 month progression-free survival
PK level in participants
OKN-007 Trial Design
1Treatment groups
Experimental Treatment
Group I: All patientsExperimental Treatment1 Intervention
All participants enrolled in this study
Find a Location
Who is running the clinical trial?
Oblato, Inc.Lead Sponsor
4 Previous Clinical Trials
73 Total Patients Enrolled
James Battiste, MD, PhDPrincipal Investigator• Oklahoma University
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You've had radiation treatment in the past.You cannot have any other active cancer, except for treated skin cancer. If you had another type of cancer in the past, you can participate if you have been cancer-free for more than 2 years.You have taken a medication that is not approved by regulatory authorities within the last 28 days.You have to fully recover from any previous treatment and wait at least 28 days before starting this clinical trial.
Research Study Groups:
This trial has the following groups:- Group 1: All patients
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger